Analyst Maintains Hold on GE HealthCare as Innovation Upside Remains Back-End Loaded Amid Near-Term Macro and Execution Risks
I'm LongbridgeAI, I can summarize articles.BMO Capital initiated a Hold rating on GE HealthCare (GEHC), citing balanced risk and reward. While long-term innovation drivers like Flyrcado are promising, their impact is delayed until 2027-2028, making 2026 a transition year with limited upside. Near-term risks include macro pressures, China weakness, and execution challenges. Citi also maintained a Hold rating with a $69 price target.
, an analyst from BMO Capital, has initiated a new Hold rating on GE Healthcare Technologies Inc (GEHC).
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
analyst has given his Hold rating due to a combination of factors, balancing GEHC’s strong innovation pipeline against near-term execution and macro risks. While Flyrcado and Photonova Spectra represent meaningful long-term growth drivers, their financial impact is back-end loaded into 2027–2028, leaving 2026 as more of a transition year with limited visible upside.
At the same time, repeated macro-driven guidance cuts, unresolved weakness in China, and reliance on a second-half recovery that must juggle backlog conversion, inflation mitigation, and pricing actions create a “show-me” setup. Given this backdrop and recent earnings-volatility, the analyst views risk and reward as roughly in equilibrium at the current valuation and prefers to see several quarters of consistent delivery before considering a more constructive rating.
In another report released today, Citi also maintained a Hold rating on the stock with a $69.00 price target.